This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
GILD vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GILD vs. ILMN: Which Stock Is the Better Value Option?
Is Gilead Sciences, Inc. (GILD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?
5 Stocks to Buy as Coronavirus Vaccine in Human Trails Ramp Up
by Zacks Equity Research
As drug makers race to develop vaccine to fight coronavirus, we shortlist five stocks that are poised to grow on progress in clinical trials.
3 Sector ETFs Gaining Momentum in May
by Sanghamitra Saha
After a wobbly start, Wall Street steadied in May. These sector ETFs contributed the most in Wall Street recovery on Monday.
Top ETF Stories of April Likely to Hit Headlines Again in May
by Sanghamitra Saha
Energy, gold, online retail and biotech were the most-discussed ETF areas in April and could continue to be so in May.
Remdesivir Gets Emergency Approval: What's In Store for Gilead?
by Zacks Equity Research
In a short span of time, Gilead's Remdesivir has been successful in treating some coronavirus patients. But will this give a boost to the pharmaceutical giant?
Gilead (GILD) Q1 Earnings Top, Coronavirus Candidate in Focus
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the first quarter but the uncertain outlook for the year dampens investors' hopes.
ETF Strategies to Follow With U.S. Economy Slowly Reopening
by Sanghamitra Saha
As the U.S. economy is gradually reopening, these investment areas should perform well.
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
The Zacks Analyst Blog Highlights: Amazon, Apple, Gilead Sciences, Amgen and Visa
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Apple, Gilead Sciences, Amgen and Visa
ETF Asset Report of Coronavirus-Inflicted April
by Sanghamitra Saha
These ETF areas have gained or lost assets in the month of April.
5 Top-Performing ETF Areas of April That Are Up At Least 25%
by Sanghamitra Saha
These ETF areas showered gains in the lockdown-infected April.
Amazon Misses on Earnings, Apple Beats but Trades Lower
by Mark Vickery
Amazon came in well below earnings estimates, Apple beats on both top & bottom, plus results from Gilead, Amgen and Visa.
Gilead Sciences (GILD) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 6.33% and 2.61%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Biotech ETFs Gain on New Positive Data for Gilead's Remdesivir
by Sweta Jaiswal, FRM
As the coronavirus continues to spread, the latest positive data on remdesivir is some relief in such challenging times.
The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences
Stock Market News for Apr 30, 2020
by Zacks Equity Research
U.S. stocks closed sharply higher on Wednesday following positive clinical trial data of a drug for potential coronavirus treatment.
Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat
by Ritujay Ghosh
A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.
5 Small-Cap ETFs Beating S&P 500 in April
by Sanghamitra Saha
Extension of the paycheck protection program, some forgivable loans, strong dollar and the talks of reopening of the economy supported the small-cap ETFs in April.
Leveraged Small-Cap and Inverse Leveraged Gold Miners: 2 ETFs to Watch on Outsized Volume
by Sanghamitra Saha
URTY and JDST have seen elevated trading volume on Wednesday.
Should You Buy Gilead Sciences (GILD) Ahead of Earnings?
by Zacks Equity Research
Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Gilead's Coronavirus Drug Shows Positive Data
by Zacks Equity Research
Gilead's Coronavirus Drug Shows Positive Data
Positive Data for Gilead's (GILD) Remdesivir; Plus Q1 for BA, GE
by Mark Vickery
This is obviously remarkably good news for COVID-19 suffers, the general public in the throes of this pandemic, and of course Gilead itself.
Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More
by Zacks Equity Research
Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.
Top Stock Research Reports for Cisco, Abbott, NextEra & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Abbott Laboratories (ABT) and NextEra Energy (NEE).